| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
PhotoCure |
| Information provided by: | PhotoCure |
| ClinicalTrials.gov Identifier: | NCT00496171 |
Purpose
The purpose of the study is to determine the most effective formulation of HAL for release of hexaminolevulinate to the cervical epithelium at different doses.
| Condition |
|
Healthy |
| ChemIDplus related topics: | Hexyl 5-aminolevulinate |
| Study Type: | Observational |
| Study Design: | Natural History, Cross-Sectional, Defined Population, Prospective Study |
| Official Title: | A Phase I Hexaminolevulinate (HAL) Dose-Finding Study Applying Different Formulations to the Cervix in Healthy Volunteers |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Claes G Tropé, MD PhD | +4722934000 | c.g.trope@medisin.uio.no |
| Norway | |||||
| Riks-Radium University Hospital | Not yet recruiting | ||||
| Oslo, Norway | |||||
| Sub-Investigator: Kern Janne, MD PhD | |||||
| Sub-Investigator: Gunnar Kristensen, MD PhD | |||||
| Sub-Investigator: Even Angell-Petersen, MSc PhD | |||||
| PhotoCure |
| Principal Investigator: | Claes G Tropé, MD PhD | Riks-Radium University Hospital |
More Information
| Study ID Numbers: | PC CE102/07 |
| First Received: | July 3, 2007 |
| Last Updated: | July 3, 2007 |
| ClinicalTrials.gov Identifier: | NCT00496171 |
| Health Authority: | Norway: Norwegian Medicines Agency; Norway: The National Committees for Research Ethics in Norway |
|
|
